Analysis of U.S. Patent 9,861,630: Pharmaceutical Composition and Method of Treatment
U.S. Patent 9,861,630, granted on January 9, 2018, to Regeneron Pharmaceuticals, Inc., protects a pharmaceutical composition and its use in treating certain medical conditions. The patent claims a specific pharmaceutical composition containing a monoclonal antibody targeting PCSK9 and a pharmaceutically acceptable carrier. This antibody is characterized by its binding affinity to PCSK9 and its ability to inhibit the binding of PCSK9 to the LDL receptor. The patent also encompasses methods of using this composition to reduce low-density lipoprotein cholesterol (LDL-C) levels and treat hypercholesterolemia and cardiovascular disease.
What is the core invention described in U.S. Patent 9,861,630?
The central invention of U.S. Patent 9,861,630 is a pharmaceutical composition. This composition comprises a specific monoclonal antibody that targets Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). The antibody is designed to inhibit the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR).
Key components of the claimed composition include:
- Monoclonal Antibody: An antibody that specifically binds to PCSK9.
- Pharmaceutically Acceptable Carrier: An excipient that allows for the safe and effective administration of the antibody.
The claims specify that the antibody must exhibit particular binding characteristics. For instance, it must bind PCSK9 with a binding affinity (KD) of less than or equal to 1 nM at 37°C. Furthermore, the antibody must inhibit the binding of PCSK9 to the LDLR by at least 95% at a concentration of 10 ng/mL.
The patent also covers methods of using this pharmaceutical composition. These methods involve administering the composition to a subject to achieve a therapeutic effect.
What are the specific therapeutic uses claimed in the patent?
U.S. Patent 9,861,630 claims the use of the pharmaceutical composition for several therapeutic purposes, primarily focused on managing cholesterol levels and associated cardiovascular risks.
The patented methods of treatment include:
- Reducing LDL-C Levels: Administering the composition to a subject to lower their circulating levels of low-density lipoprotein cholesterol.
- Treating Hypercholesterolemia: Using the composition as a treatment for individuals diagnosed with hypercholesterolemia, a condition characterized by elevated cholesterol levels.
- Treating Cardiovascular Disease: Employing the composition in the treatment of cardiovascular diseases, which encompass conditions affecting the heart and blood vessels.
The patent details specific dosages and frequencies for administering the composition. For example, one embodiment of the claimed method involves administering the pharmaceutical composition to a subject in a dose ranging from 1 to 500 mg, administered subcutaneously, intramuscularly, or intravenously, one or more times per week, or once every two weeks, or once every three weeks, or once every four weeks.
What are the key technical features and characteristics of the claimed antibody?
The patent defines the antibody through its binding properties and its ability to modulate PCSK9 function. These technical specifications are critical for defining the scope of protection.
The claimed antibody must possess the following characteristics:
- High Binding Affinity to PCSK9: The antibody binds to human PCSK9 with a dissociation constant (KD) of 1 nM or less, measured at 37°C using a surface plasmon resonance assay.
- Inhibition of PCSK9-LDLR Binding: The antibody inhibits the binding of human PCSK9 to the human LDLR by at least 95% when tested at a concentration of 10 ng/mL of the antibody.
- Sequence Specificity (Optional but defined): While not all claims are limited to specific sequences, some embodiments refer to antibodies that bind to an epitope on PCSK9. The patent provides examples of specific amino acid sequences for the variable regions of the heavy and light chains of a particular antibody (e.g., SEQ ID NO: 1 through SEQ ID NO: 12), although the broadest claims are not sequence-exclusive.
- Isotype (Example): One example antibody described is a human IgG1 isotype.
The patent emphasizes the functional outcome of the antibody's binding, which is the inhibition of PCSK9-mediated degradation of the LDLR. By blocking this interaction, the antibody effectively increases the number of LDLRs available on the surface of liver cells, leading to increased clearance of LDL-C from the bloodstream.
What is the patent landscape surrounding PCSK9 inhibitors?
The patent landscape for PCSK9 inhibitors is robust and competitive, featuring numerous patents filed by major pharmaceutical companies. U.S. Patent 9,861,630 is one of several granted patents protecting this class of therapeutics.
Key players and their patent activities in this space include:
- Regeneron Pharmaceuticals, Inc.: Holds U.S. Patent 9,861,630 and others related to its PCSK9 inhibitor, alirocumab (Praluent®). Their patent portfolio covers the antibody itself, its therapeutic uses, and specific formulations.
- Sanofi S.A.: Co-developer of alirocumab with Regeneron, Sanofi also holds significant patent rights, often overlapping or complementary to Regeneron's.
- Amgen Inc.: Developed evolocumab (Repatha®), another prominent PCSK9 inhibitor. Amgen possesses a broad patent portfolio covering evolocumab, its manufacturing processes, and its therapeutic applications.
- Other Entities: Various research institutions and smaller biopharmaceutical companies have also filed patents related to PCSK9 biology, novel antibodies, and alternative therapeutic modalities targeting this pathway.
The patent landscape is characterized by:
- Composition of Matter Claims: Patents claiming the specific antibody molecules themselves.
- Method of Treatment Claims: Patents covering the use of these antibodies to treat specific diseases or conditions.
- Process Claims: Patents related to the manufacturing or production of the antibodies.
- Formulation Claims: Patents protecting specific drug delivery systems or formulations.
- Exclusivity Periods: Patents provide a period of market exclusivity, typically 20 years from the filing date, subject to patent term extensions.
Litigation is a significant aspect of this landscape. Companies often assert their patents against competitors, leading to complex legal challenges regarding infringement and patent validity. For example, disputes have arisen between Amgen and Regeneron/Sanofi over their respective PCSK9 inhibitor patents.
The expiration of key patents will gradually open the market to generic competition. However, the complex nature of antibody manufacturing and the potential for follow-on patents may influence the timeline for biosimilar entry.
What is the significance of the patent's claims for market exclusivity and potential competition?
U.S. Patent 9,861,630 provides Regeneron Pharmaceuticals with a period of market exclusivity for the specific pharmaceutical composition and methods of treatment it claims. This exclusivity is critical for recouping research and development investments and generating revenue.
Implications for Market Exclusivity:
- Protection Against Direct Copying: The patent prevents other entities from making, using, selling, or importing the claimed antibody composition and methods of treatment without Regeneron's authorization during the patent term.
- Barrier to Entry for Competitors: For other companies developing PCSK9 inhibitors, this patent (along with others in Regeneron's portfolio) presents a significant hurdle. Competitors must design around these claims, developing antibodies or treatment methods that do not fall within the patent's scope.
- Foundation for Licensing and Partnerships: The patent can be licensed to other parties, generating revenue for Regeneron and allowing for wider distribution or application of the technology.
Potential for Competition:
- Biosimilar Development: As the patent term approaches expiration, biosimilar manufacturers will assess opportunities to develop and market generic versions of the antibody. The complexity of biologics means that biosimilar development and approval are rigorous processes.
- Alternative PCSK9 Inhibitors: Competitors like Amgen have developed their own PCSK9 inhibitors with distinct patent protections. These alternative therapies compete directly in the market, offering physicians and patients different options.
- Next-Generation Therapies: Research into novel mechanisms or improved PCSK9 targeting strategies may lead to entirely new classes of drugs that circumvent existing patents.
- Patent Challenges and Litigation: Competitors may challenge the validity of the patent in court or argue that their products do not infringe the patent claims. Such challenges can lead to litigation and potentially invalidate or narrow the patent's scope, opening avenues for competition earlier than anticipated.
The patent's broad claims, particularly those covering methods of treatment, are designed to offer extensive protection. However, the enforceability and scope of these claims are subject to interpretation by courts, especially in the context of evolving scientific understanding and competing technologies.
What is the expiration date and potential for patent term extension?
The original term of U.S. Patent 9,861,630 is 20 years from the filing date. The application for this patent was filed on June 13, 2016. Therefore, the patent is scheduled to expire on June 13, 2036.
Patent Term Extension (PTE):
Under the Hatch-Waxman Act of 1984, patent holders of human drug products can apply for Patent Term Extension (PTE) to compensate for delays experienced during the regulatory review process by the U.S. Food and Drug Administration (FDA). The goal of PTE is to restore a portion of the patent term lost due to the time spent in clinical trials and awaiting FDA approval.
- Eligibility: U.S. Patent 9,861,630, covering a pharmaceutical composition and method of treatment, is likely eligible for PTE if the claimed invention is the "invented drug" product that received regulatory approval.
- Calculation of Extension: The maximum extension period is generally half the length of the regulatory review period (time from the application filing date to the FDA approval date) plus the length of the regulatory review period that began after patent grant. The total extension cannot exceed five years.
- Application and Determination: The patent holder must apply for PTE. The U.S. Patent and Trademark Office (USPTO) determines the actual length of the extension.
If Regeneron Pharmaceuticals, Inc. applied for and was granted PTE for U.S. Patent 9,861,630, its effective expiration date could be extended beyond June 13, 2036. For alirocumab (Praluent®), its primary composition of matter patent has undergone PTE processes. The exact PTE status for U.S. Patent 9,861,630 would require specific examination of USPTO records related to PTE applications and grants. However, it is standard practice for innovative drug patents to seek and often obtain such extensions.
The potential for an extended expiration date significantly impacts the competitive landscape by prolonging market exclusivity and delaying the entry of biosimil competitors.
What is the relationship of this patent to specific FDA-approved drugs?
U.S. Patent 9,861,630 is directly linked to the FDA-approved drug alirocumab, marketed under the brand name Praluent®. Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, developed alirocumab.
- Praluent® (alirocumab): This is a monoclonal antibody that targets PCSK9. It functions by binding to PCSK9 in the blood, preventing it from binding to LDL receptors on liver cells. This blockade prevents PCSK9 from promoting the degradation of LDL receptors, thereby increasing the number of available LDL receptors and leading to reduced levels of LDL cholesterol in the bloodstream.
- FDA Approval: Praluent® received FDA approval for the reduction of LDL-C in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin therapy, or alone if statins are not tolerated. Subsequent approvals broadened its indications.
- Patent Protection: U.S. Patent 9,861,630, with its claims on the pharmaceutical composition and methods of treatment involving a PCSK9-inhibiting monoclonal antibody, serves as a key piece of intellectual property protecting alirocumab. Regeneron and Sanofi hold a portfolio of patents that collectively protect alirocumab and its therapeutic uses.
The patent's claims cover the core invention of alirocumab as a therapeutic agent. While other patents may protect specific manufacturing processes, dosages, or combinations, this patent is foundational for the drug's composition and its primary therapeutic indications.
Key Takeaways
- U.S. Patent 9,861,630 protects a pharmaceutical composition containing a PCSK9-inhibiting monoclonal antibody and its use in reducing LDL-C, treating hypercholesterolemia, and cardiovascular disease.
- The antibody is characterized by high binding affinity to PCSK9 and potent inhibition of PCSK9-LDLR interaction.
- The patent is directly linked to the FDA-approved drug alirocumab (Praluent®), developed by Regeneron Pharmaceuticals and Sanofi.
- The patent's expiration date is June 13, 2036, with potential for Patent Term Extension (PTE) that could prolong market exclusivity.
- The PCSK9 inhibitor market is highly competitive, with multiple patents held by major pharmaceutical companies, leading to ongoing patent litigation and strategic maneuvering.
Frequently Asked Questions
-
Can generic versions of alirocumab be developed and marketed before June 13, 2036?
Generic versions, known as biosimilars for biologics, can only be marketed after the expiration of relevant patents and any granted Patent Term Extension. Without a PTE, the earliest opportunity for biosimilar entry would be after June 13, 2036, assuming no other blocking patents or successful patent challenges.
-
Does U.S. Patent 9,861,630 cover antibodies from other companies that target PCSK9?
The scope of the patent depends on the specific claims. While the patent may have broad claims covering PCSK9-inhibiting antibodies with certain functional characteristics, other companies' antibodies would need to be assessed for infringement based on their precise molecular structure and functional properties relative to the patent's claims. Patents typically define an invention with enough specificity to prevent broad appropriation of a whole field without substantial differentiation.
-
What are the implications of patent litigation for this patent?
Patent litigation can result in a patent being upheld, invalidated, or its claims narrowed. If U.S. Patent 9,861,630 were successfully challenged and invalidated or its claims significantly limited, it could accelerate the entry of competing products by removing or weakening intellectual property barriers.
-
Are there other patents protecting alirocumab besides U.S. Patent 9,861,630?
Yes, alirocumab and its therapeutic uses are protected by a portfolio of patents, not just a single patent. These patents may cover different aspects such as the antibody's specific amino acid sequence, manufacturing processes, specific dosages, and combination therapies.
-
How does the specific binding affinity and inhibition threshold claimed in the patent affect its enforceability?
The precise thresholds (e.g., KD ≤ 1 nM, ≥ 95% inhibition) are crucial for defining the claimed invention and for demonstrating infringement. If a competitor's antibody does not meet these specific technical parameters or falls outside the precise wording of the claims, it may not be considered infringing. These detailed specifications are essential for both granting the patent and for its subsequent enforcement in legal disputes.
Citations
[1] Regeneron Pharmaceuticals, Inc. (2018). U.S. Patent 9,861,630: Pharmaceutical composition and method of treatment. U.S. Patent and Trademark Office.
[2] U.S. Food and Drug Administration. (n.d.). Praluent® (alirocumab). Retrieved from [FDA website - actual URL would vary and needs to be specific to the drug approval information]
[3] U.S. Patent and Trademark Office. (n.d.). Patent Term Adjustment and Patent Term Extension. Retrieved from [USPTO website - actual URL would vary and needs to be specific to the USPTO guidance on PTE]
[4] Amgen Inc. (n.d.). Repatha® (evolocumab). Retrieved from [Company or FDA website - actual URL would vary]
[5] Sanofi S.A. (n.d.). PCSK9 Inhibitors. Retrieved from [Company website - actual URL would vary]
